Cancer Research in Switzerland - Krebsliga Schweiz

More documents

Recommendations

Info

152 Zucca Emanuele | A prospective clinico-pathologic study of primary mediastinal B-cell lymphoma (PMBCL) (OCS 01709-04-2005) The need for radiotherapy in patients with primary mediastinal B-cell lymphoma (PMBCL) treated with the modern immunochemotherapy regimens is an unresolved issue that is becoming more and more controversial. The IELSG-26 study (International Extranodal Lymphoma Study Group) aims to obtain data on treatment outcomes following anthracycline-containing immunochemotherapy regimens, with or without mediastinal radiotherapy, the latter depending upon the practice of the participating institutions. Main endpoint of the study is to determine the response rate evaluated by positron emission tomography scans (18FDG PET-CT) following chemo-immunotherapy. The study enrolled 125 patients with PMBCL treated using either the R-CHOP or the R-MACOP-B chemotherapeutic regimen; 123 received consolidation radiotherapy. The recruitment ended in November 2010. Treatment results were monitored using 18-F-FDG PET-CT scan performed baseline, at 3– 4 weeks after the end of chemotherapy and 2 months post-radio-therapy, respectively. The PET CR was defined according to the criteria of the International Harmonization Project (Cheson et al., Journal of Clinical Oncology 2007). The central PET images qualitative review by an expert nuclear medicine specialist is ongoing and has included 61 patients up to now. The PET-CT scan became negative at the end of chemotherapy in only 49 % of patients. The agreement between central review and “on site” reporting was 70 % (43/61) with increase on central review of the positive cases (from 39 % to 51 %) due mainly to the “on site” underestimation of the minimal residual 18FDG activity at the end of treatment. The rate of patients with persistent PET-positive scans at the end of immunotherapy in this study seems higher than in the non-mediastinal large cell lymphoma. This might partly depend on the relatively short interval between end of chemotherapy and imaging (which may affect the rate of false positive scans). Analysis of the PET response and its correlation with clinical outcome in the entire study population is awaited. It will be of paramount importance for the design of future clinical trials aimed at defining the increasingly debated role of radiotherapy. Project coordinator PD Dr. Emanuele Zucca International Extranodal Lymphoma Study Group (IELSG) Istituto oncologico della Svizzera italiana (IOSI) Ospedale San Giovanni CH-6500 Bellinzona Phone +41 (0)91 811 90 40 Fax +41 (0)91 811 91 82 emanuelezucca@yahoo.com Further completed research projects from July 2008 to December 2010 Cozzi Luca | OCS 01821-02-2006 | CHF 80,800.– Servizio di fisica medica, Istituto oncologico della Svizzera italiana (IOSI), Ospedale regionale di Bellinzona e valli, Bellinzona Heterogeneity management in advanced algorithms for photon dose calculation and the clinical impact on breast and lung cancer radiotherapy. Validation of existing models against experimental studies, Monte Carlo simulations and determination of potential Garayoa Elisa Garcia | KLS 02040-02-2007 | CHF 150,700.– Zentrum für radiopharmazeutische Wissenschaften, Paul Scherrer Institut (PSI), Villigen Development of new bombesin-based radiopharmaceuticals with improved pharmacokinetics as potential imaging and therapeutic agents for bombesin receptor-positive tumours Hoek Keith | OCS 01927-08-2006 | CHF 145,500.– Dermatologische Klinik, Medizinbereich Trauma-Derma-Rheuma-Plastische Chirurgie, UniversitätsSpital Zürich, Zürich Clinical implications of Wnt signal-driven regulation of melanoma metastatic potential Stahel Rolf A. | OCS 01915-08-2006 | CHF 148,800.– Klinik und Poliklinik für Onkologie, Medizinbereich Innere Medizin-Onkologie, UniversitätsSpital Zürich, Zürich SAKK trial 17/04 on neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma (MPM) with or without hemithoracic radiotherapy, including translational research
Clinical research List of approved research projects in 2009/2010 Total funds allocated CHF 7,097,850.– Aebi Stefan | KFS 02689-08-2010 | CHF 260,300.– Medizinische Onkologie, Luzerner Kantonsspital, Luzern IBCSG 39-10 / MA.32: A phase III randomized trial of the effect of metformin versus placebo on recurrence and survival in early stage breast cancer Anderle Pedone Pascale | OCS 02303-08-2008 | CHF 195,000.– Institut für Biochemie und molekulare Medizin, Universität Bern, Bern Exploiting transporters in the tumor-stroma interface to aim for a more efficient chemotherapy Bertoni Francesco | KLS 02403-02-2009 | CHF 150,000.– Gruppo genomica funzionale e linfomi, Laboratorio di oncologia sperimentale, Istituto oncologico della Svizzera italiana (IOSI), Bellinzona Anaplastic large cell lymphoma: One or more entities? Bourquin Jean-Pierre | KFS 02453-08-2009 | CHF 125,500.– Abteilung Onkologie, Kinderspital Zürich, Universitäts-Kinderkliniken, Zürich Pre-clinical evaluation of a new pharmacological approach using obatoclax for chemosensitization of drug resistant childhood acute lymphoblastic leukemia Bourquin Jean-Pierre | KFS 02583-02-2010 | CHF 238,000.– Abteilung Onkologie, Kinderspital Zürich, Universitäts-Kinderkliniken, Zürich Comprehensive analysis of the cell surface proteome of childhood refractory ALL for identification of new diagnostic and therapeutic targets Carbone Giuseppina | KFS 02573-02-2010 | CHF 305,100.– Laboratorio di oncologia sperimentale, Istituto oncologico della Svizzera italiana (IOSI), Bellinzona Deregulated ETS transcriptional network and clinical implications for prostate cancer progression Cathomas Gieri | KLS 02392-02-2009 | CHF 248,550.– Kantonales Institut für Pathologie, Kantonsspital Liestal, Liestal The role of polyomavirus in the development of Merkel cell and epithelial skin carcinomas Cavalli Franco | KLS 02399-02-2009 | CHF 157,550.– Istituto oncologico della Svizzera italiana (IOSI), Ospedale San Giovanni, Bellinzona A randomised phase II trial on primary chemotherapy with high-dose methotrexate (HD-MTX) and high-dose cytarabine (HD-AraC) with or without thiotepa and with or without rituximab, followed by brain irradiation vs. high-dose chemotherapy supported by autologous stem cell transplantation (ASCT) for immunocompetent patients with newly diagnosed primary central nervous system lymphoma (PCNSL) Foti Michelangelo | KFS 02502-08-2009 | CHF 307,400.– Département de physiologie cellulaire et métabolisme, Faculté de médecine, Centre médical universitaire (CMU), Université de Genève, Genève Role of dietary free fatty acids, microRNA-21 and PTEN in liver cancer Gruber Günther | KFS 02527-02-2010 | CHF 150,700.– Institut für Radiotherapie Zürich, Klinik Hirslanden, Zürich BIG 3-07: A randomised phase-III study of radiation doses and fractionation schedules for ductal carcinoma in situ (DCIS) of the breast Hegi Monika E. | KFS 02670-08-2010 | CHF 198,300.– Laboratoire de biologie et génétique des tumeurs, Service de neurochirurgie, Centre hospitalier universitaire vaudois (CHUV), Lausanne Targeting the EGFR/PI3K pathway in glioblastoma, what matters? Heim Markus Hermann | KLS 02522-02-2010 | CHF 218,300.– Klinik für Gastroenterologie und Hepatologie, Universitätsspital Basel, Basel Hepatocarcinogenesis in chronic hepatitis C 153
Page 1 and 2:
Cancer Research in Switzerland A pu
Page 3 and 4:
Cancer Research in Switzerland
Page 5 and 6:
Basic biomedical research 55 Cancer
Page 7 and 8:
policy work and was in charge of de
Page 9 and 10:
The main focus of the research fund
Page 11 and 12:
gramme research funding decreased b
Page 13 and 14:
Table 2 Distribution of funds for i
Page 15 and 16:
Funding patient-centred research Pa
Page 17 and 18:
value was not clearly discernible.
Page 19 and 20:
New organization of the Foundation
Page 21 and 22:
The board of the Foundation Cancer
Page 23 and 24:
The president of the Scientific Com
Page 25 and 26:
Prof. Martin Pruschy, PhD Departmen
Page 27 and 28:
Swartz wants to find out how tumour
Page 29 and 30:
The scientific and medical research
Page 31 and 32:
3. The original order/sequence of t
Page 33 and 34:
As a federation, the Cancer League
Page 35 and 36:
List of funded research projects, i
Page 37 and 38:
Zippelius Alfred | 2009: CHF 100,00
Page 39 and 40:
Kridel Robert | 2010: CHF 100,000.-
Page 41 and 42:
Thurgau Cancer League Biotechnologi
Page 43 and 44:
Weller Michael | 2010: CHF 65,828.-
Page 45 and 46:
manageable funding of individual pr
Page 47 and 48:
enhances breast cancer cell motilit
Page 49 and 50:
Rüegg Curzio et al. | Tumor-mediat
Page 51 and 52:
International Clinical Cancer Resea
Page 53 and 54:
in PHIV were shown for Hodgkin’s
Page 55:
Zucca Emanuele et al. | Internation
Page 58 and 59:
56 “hierarchical structure” of
Page 60 and 61:
58 the attempt should be made to st
Page 62 and 63:
60 Gönczy Pierre | KLS 0202402
Page 64 and 65:
62 Romero Pedro | OCS 020110220
Page 66 and 67:
64 Beermann Friedrich | In vivo scr
Page 68 and 69:
66 Christofori Gerhard | Podoplanin
Page 70 and 71:
68 Frei Christian | The function of
Page 72 and 73:
70 cell, this novel mechanism serve
Page 74 and 75:
72 Results The induction of viral p
Page 76 and 77:
74 Hübscher Ulrich | Repair of oxi
Page 78 and 79:
76 Methods and experimental approac
Page 80 and 81:
78 of cMyc and/or NMyc and demo
Page 82 and 83:
80 In summary, this work improves o
Page 84 and 85:
82 Pruschy Martin | Microtubule int
Page 86 and 87:
84 Renner Christoph | Selective inh
Page 88 and 89:
86 Goal Here we build on these obse
Page 90 and 91:
88 by TDG prevents efficient downst
Page 92 and 93:
90 To address these questions, we a
Page 94 and 95:
92 Translational relevance The resu
Page 96 and 97:
94 Grünberg Jürgen | KFS 025460
Page 98 and 99:
96 Tschan Mario P. | KFS 0248608
Page 100 and 101:
98 Boyman Onur | Preclinical testin
Page 102 and 103:
100 Constam Daniel | Role of activi
Page 104 and 105: 102 this study we will examine the
Page 106 and 107: 104 Janscak Pavel | Study of the ro
Page 108 and 109: 106 Müller Anne | The molecular pa
Page 110 and 111: 108 Radtke Freddy | The role of Not
Page 112 and 113: 110 Schär Primo | DNA repair, epig
Page 114 and 115: 112 In this project we will investi
Page 116 and 117: 114
Page 118 and 119: 116 and Research). Other financial
Page 120 and 121: 118 be totally unaffordable for aca
Page 122 and 123: 120 Clinical research List of compl
Page 124 and 125: 122 Hunger Robert E. | OCS 02262-08
Page 126 and 127: 124 Clinical research Presentation
Page 128 and 129: 126 Benhattar Jean | Identification
Page 130 and 131: 128 Bertoni Francesco | Genome-wide
Page 132 and 133: 130 Interpretation ESA treatment in
Page 134 and 135: 132 Our results could pave the way
Page 136 and 137: 134 new drugs that specifically tar
Page 138 and 139: 136 slides in two different concent
Page 140 and 141: 138 Conclusions A strong network of
Page 142 and 143: 140 tions introduced to ARE motifs
Page 144 and 145: 142 Müller Beatrice U. | The maste
Page 146 and 147: 144 A novel method was developed fo
Page 148 and 149: 146 (SAKK 35-98) the Swiss Group fo
Page 150 and 151: 148 Timmermann Beate | Prospective
Page 152 and 153: 150 recurrence of the disease, we a
Page 156 and 157: 154 Heinimann Karl | KFS 02489-08-2
Page 158 and 159: 156 Riggi Nicolò | BIL KFS 02717-0
Page 160 and 161: 158 activity at the single cell lev
Page 162 and 163: 160 Our research projects aim at un
Page 164 and 165: 162 Körner Meike | In vitro evalua
Page 166 and 167: 164 Nadal David | Is endemic Burkit
Page 168 and 169: 166 (> 50.000/patient). For their a
Page 170 and 171: 168 Zeller Rolf | Functional analys
Page 172 and 173: 170
Page 174 and 175: 172 area of health services researc
Page 176 and 177: 174 The financing of palliative car
Page 178 and 179: 176 National Strategy for Palliativ
Page 180 and 181: 178 Psychosocial research List of c
Page 182 and 183: 180 Within the patient group, level
Page 184 and 185: 182 Further, the results suggest th
Page 186 and 187: 184 It is in this context that the
Page 188 and 189: 186 Recommendation Female spouses o
Page 190 and 191: 188 Psychosocial research Presentat
Page 192 and 193: 190 rates communication skills rema
Page 195 and 196: Epidemiological research Epidemiolo
Page 197 and 198: data from cancer registries. In the
Page 199 and 200: The importance of cancer registries
Page 201 and 202: Ess Silvia | Patterns of care and s
Page 203 and 204: Epidemiological research List of ap
Page 205 and 206:
Impact This work will serve as the
Page 207 and 208:
Thürlimann Beat | Management of br
show all

Cancer Research in Switzerland - Krebsliga Schweiz

Create successful ePaper yourself

Delete template?

Save as template?